CLO23-046: Pooled Outcomes of Anti-BRAF Agents in Advanced Stage Colorectal Cancer

Authors:
Mackenzie Taychert University of Missouri, Columbia, MO

Search for other papers by Mackenzie Taychert in
Current site
Google Scholar
PubMed Close
 Doctorate
,
Ankita Aggarwal University of Missouri, Columbia, MO

Search for other papers by Ankita Aggarwal in
Current site
Google Scholar
PubMed Close
 Doctorate
,
David Tabagari University of Missouri, Columbia, MO

Search for other papers by David Tabagari in
Current site
Google Scholar
PubMed Close
 Doctorate
,
Urja Nagadia University of Missouri, Columbia, MO

Search for other papers by Urja Nagadia in
Current site
Google Scholar
PubMed Close
 Doctorate
,
Sai Gajagowni University of Missouri, Columbia, MO

Search for other papers by Sai Gajagowni in
Current site
Google Scholar
PubMed Close
 Bachelors
,
Venkata Vosuri University of Missouri, Columbia, MO

Search for other papers by Venkata Vosuri in
Current site
Google Scholar
PubMed Close
 Doctorate
, and
Kushal Naha University of Missouri, Columbia, MO

Search for other papers by Kushal Naha in
Current site
Google Scholar
PubMed Close
 Doctorate
Volume/Issue:
Volume 21: Issue 3.5
Online Publication Date:
31 Mar 2023
DOI:
https://doi.org/10.6004/jnccn.2022.7158
Full access

Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy are suboptimal. Targeted treatment with anti-BRAF agents plus anti-EGFR antibodies/chemotherapy have shown promising results based on a smaller number of studies. Here we report a pooled estimate of clinical activity of anti-BRAF agents plus anti-EGFR antibodies/chemotherapy in advanced CRC patients based on published phase II/III trials so far. Methods: PubMed, EMBASE, Cochrane review, and clinicaltrials.gov databases were searched for phase II/III clinical trials studying anti-BRAF agents plus anti-EGFR antibodies/chemotherapy in the second or third line setting for metastatic colorectal cancers. Data were extracted based on Reviews and Meta- Analysis guidelines. DerSimonian-Laird (DL) random effects model was used to estimate the pooled proportion of patients achieving objective response rate (ORR), pooled proportion of patients experiencing therapy related adverse events (TRAEs grade ≥ 3), pooled median progression free survival (PFS) and weights were estimated using inverse variance method. Statistical heterogeneity was calculated using the I2 and chi-squared test. Outcomes were calculated by using ‘Metafor’ and ‘Meta’ packages by R-Studio and “CRAN” project. Results: Four studies with a total of 673 patients who received anti-BRAF agents plus anti-EGFR antibodies/chemotherapy were analyzed. Median age of patients who received treatment was 61 yrs. The pooled proportion of patients who achieved ORR was 21% (95% CI 16% to 25%). Pooled Median PFS was about 4.28 (95% CI, 3.92- 4.6) months and the pooled proportion of patients who experienced adverse events (TRAEs grade ≥ 3) during the treatment was 62% (95% CI 53% to 70%). Conclusions: BRAF-targeted agents plus anti-EGFR antibodies/chemotherapy shown encouraging results with modest improvement in ORR and progression free survival in advanced stage colorectal cancers.

Corresponding Author: Mackenzie Taycher

Email: mltfbp@umsystem.edu
  • Collapse
  • Expand
Copyright:
Copyright © 2023 by the National Comprehensive Cancer Network 2023
Article Category:
Abstract
Print Publication Date:
31 Mar 2023
Online Publication Date:
31 Mar 2023
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 159 159 10
PDF Downloads 0 0 0
EPUB Downloads 0 0 0